These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 33613571)
21. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial. Cutolo M; Myerson GE; Fleischmann RM; Lioté F; Díaz-González F; Van den Bosch F; Marzo-Ortega H; Feist E; Shah K; Hu C; Stevens RM; Poder A J Rheumatol; 2016 Sep; 43(9):1724-34. PubMed ID: 27422893 [TBL] [Abstract][Full Text] [Related]
22. Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet's disease in Taiwan. Hu YC; Yang YH; Lin YT; Wang LC; Yu HH; Lee JH; Chiang BL BMC Pediatr; 2019 Jul; 19(1):232. PubMed ID: 31296171 [TBL] [Abstract][Full Text] [Related]
23. Apremilast to treat oral ulcers in Behçet syndrome. Yazici H Drugs Today (Barc); 2020 May; 56(5):303-310. PubMed ID: 32406877 [TBL] [Abstract][Full Text] [Related]
24. Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study. Genovese MC; Jarosova K; Cieślak D; Alper J; Kivitz A; Hough DR; Maes P; Pineda L; Chen M; Zaidi F Arthritis Rheumatol; 2015 Jul; 67(7):1703-10. PubMed ID: 25779750 [TBL] [Abstract][Full Text] [Related]
25. Off-label studies on apremilast in dermatology: a review. Maloney NJ; Zhao J; Tegtmeyer K; Lee EY; Cheng K J Dermatolog Treat; 2020 Mar; 31(2):131-140. PubMed ID: 30935262 [No Abstract] [Full Text] [Related]
26. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Edwards CJ; Blanco FJ; Crowley J; Birbara CA; Jaworski J; Aelion J; Stevens RM; Vessey A; Zhan X; Bird P Ann Rheum Dis; 2016 Jun; 75(6):1065-73. PubMed ID: 26792812 [TBL] [Abstract][Full Text] [Related]
27. Real-world use of apremilast for patients with psoriasis in Japan. Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880 [TBL] [Abstract][Full Text] [Related]
28. [Interest of Apremilast in idiopathic recurrent aphthous stomatitis: Review of two clinical cases]. Fourmond S; Gutierrez B; Gourin MP; Delaumenie S; Ly KH Rev Med Interne; 2022 May; 43(5):312-315. PubMed ID: 35219509 [TBL] [Abstract][Full Text] [Related]
29. Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Nash P; Ohson K; Walsh J; Delev N; Nguyen D; Teng L; Gómez-Reino JJ; Aelion JA; Ann Rheum Dis; 2018 May; 77(5):690-698. PubMed ID: 29343507 [TBL] [Abstract][Full Text] [Related]
30. Treatment of mucocutaneous manifestations in Behçet's disease with anakinra: a pilot open-label study. Grayson PC; Yazici Y; Merideth M; Sen HN; Davis M; Novakovich E; Joyal E; Goldbach-Mansky R; Sibley CH Arthritis Res Ther; 2017 Mar; 19(1):69. PubMed ID: 28335798 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study. Van Voorhees AS; Stein Gold L; Lebwohl M; Strober B; Lynde C; Tyring S; Cauthen A; Sofen H; Zhang Z; Paris M; Wang Y J Am Acad Dermatol; 2020 Jul; 83(1):96-103. PubMed ID: 32032692 [TBL] [Abstract][Full Text] [Related]
32. Prognosis of Behcet's syndrome among men with mucocutaneous involvement at disease onset: long-term outcome of patients enrolled in a controlled trial. Hamuryudan V; Hatemi G; Tascilar K; Sut N; Ozyazgan Y; Seyahi E; Mat C; Yurdakul S; Yazici H Rheumatology (Oxford); 2010 Jan; 49(1):173-7. PubMed ID: 19995858 [TBL] [Abstract][Full Text] [Related]
33. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Schett G; Wollenhaupt J; Papp K; Joos R; Rodrigues JF; Vessey AR; Hu C; Stevens R; de Vlam KL Arthritis Rheum; 2012 Oct; 64(10):3156-67. PubMed ID: 22806399 [TBL] [Abstract][Full Text] [Related]
34. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis. Kavanaugh A; Gladman DD; Edwards CJ; Schett G; Guerette B; Delev N; Teng L; Paris M; Mease PJ Arthritis Res Ther; 2019 May; 21(1):118. PubMed ID: 31077258 [TBL] [Abstract][Full Text] [Related]
35. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Hochfeld M; Teng LL; Schett G; Lespessailles E; Hall S J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233 [TBL] [Abstract][Full Text] [Related]
36. Apremilast in psoriasis - a prospective real-world study. Vujic I; Herman R; Sanlorenzo M; Posch C; Monshi B; Rappersberger K; Richter L J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):254-259. PubMed ID: 28925560 [TBL] [Abstract][Full Text] [Related]
37. Behçet's disease. Report of twenty-five patients from the United States with prominent mucocutaneous involvement. Mangelsdorf HC; White WL; Jorizzo JL J Am Acad Dermatol; 1996 May; 34(5 Pt 1):745-50. PubMed ID: 8632067 [TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL. Stein Gold L; Bagel J; Lebwohl M; Jackson JM; Chen R; Goncalves J; Levi E; Duffin KC J Drugs Dermatol; 2018 Feb; 17(2):221-228. PubMed ID: 29462231 [TBL] [Abstract][Full Text] [Related]